Transcatheter aortic valve replacement in patients with high aortic anguation
Increasing procedures of transcatheter aortic valve replacement (TAVR) have been performed worldwide since the approval of transcatheter valve. It has emerged as a safe and effective treatment strategy for patients with severe symptomatic aortic valve diseases who are deemed to have high surgical risk (1,2). Currently, two types of transcatheter valves are mainly used in clinical trials: balloon expandable valve (BEV) and self-expanding valve (SEV). Both of them have been reported with data of safety and efficacy from the well-conducted multicenter randomized controlled trials (RCTs), indicating favorable short- and long-term outcomes following procedure (3-7).